Akebia Therapeutics, Inc. Forecast, price target & analysts
Akebia Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Akebia Therapeutics, Inc. Classifications & Recommendation
Akebia Therapeutics, Inc. Price Target
| Target Price | $4.08 |
| Price | $0.92 |
| Potential |
344.54%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Akebia Therapeutics, Inc. 2027 .
The average Akebia Therapeutics, Inc. target price is $4.08.
This is
344.54%
register free of charge
$6.30
586.42%
register free of charge
$1.01
10.05%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Akebia Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Akebia Therapeutics, Inc. stock has an average upside potential 2027 of
344.54%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 236.20 | 200.78 |
| 47.46% | 15.00% | |
| Net Margin | -2.27% | -20.71% |
| 94.77% | 814.34% |
7 Analysts have issued a sales forecast Akebia Therapeutics, Inc. 2026 . The average Akebia Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Akebia Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Akebia Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.02 | -0.15 |
| 93.94% | 650.00% | |
| P/E | negative | |
| EV/Sales | 1.45 |
7 Analysts have issued a Akebia Therapeutics, Inc. forecast for earnings per share. The average Akebia Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Akebia Therapeutics, Inc....
Current Akebia Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WestPark Capital |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 01 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Apr 07 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Feb 25 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 06 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
WestPark Capital:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 01 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Apr 07 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Feb 25 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 06 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
